MyoKardia Inc - Strategic SWOT Analysis Review

July 2021 | 35 pages | ID: ME8F92211474EN
GlobalData

Abstracts

MyoKardia Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for the treatment of serious and rare cardiovascular diseases including heritable cardiomyopathies. Its lead drug product candidate, mavacamten, is intended for the treatment of hypertrophic cardiomyopathy (HCM). Its other pipeline product candidates include danicamtiv (formerly MYK-491) is being developed for treating genetic dilated cardiomyopathy (DCM) and systolic heart failure; MYK-224, a small molecule for treating HCM; ACT-1 for systolic heart failure, and LUS-1, for treating diastolic heart failure. The company collaborates with healthcare organizations for the development and commercialization of its pipeline products. MyoKardia is headquartered in Brisbane, California, the US.

MyoKardia Inc Key Recent Developments

Nov 25,2020: MyoKardia reports third quarter 2020 financial results
Nov 18,2020: BMS acquires biopharma firm MyoKardia for $13.1bn
Nov 11,2020: MyoKardia collaborates with the American College of Cardiology and PINNACLE/veradigm to launch patient registry of hypertrophic cardiomyopathy
Nov 04,2020: MyoKardia announces awardees of the second annual MyoSeeds Research Grants Program
Oct 06,2020: BMS to acquire biopharma firm MyoKardia for $13.1bn

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

MyoKardia Inc - Key Facts
MyoKardia Inc - Key Employees
MyoKardia Inc - Key Employee Biographies
MyoKardia Inc - Major Products and Services
MyoKardia Inc - History
MyoKardia Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
MyoKardia Inc - Business Description
MyoKardia Inc - Corporate Strategy
MyoKardia Inc - SWOT Analysis
SWOT Analysis - Overview
MyoKardia Inc - Strengths
MyoKardia Inc - Weaknesses
MyoKardia Inc - Opportunities
MyoKardia Inc - Threats
MyoKardia Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MyoKardia Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Nov 25, 2020: MyoKardia reports third quarter 2020 financial results
Nov 18, 2020: BMS acquires biopharma firm MyoKardia for $13.1bn
Nov 11, 2020: MyoKardia collaborates with the American College of Cardiology and PINNACLE/veradigm to launch patient registry of hypertrophic cardiomyopathy
Nov 04, 2020: MyoKardia announces awardees of the second annual MyoSeeds Research Grants Program
Oct 06, 2020: BMS to acquire biopharma firm MyoKardia for $13.1bn
Aug 04, 2020: MyoKardia reports second quarter 2020 financial results
Jul 06, 2020: MyoKardia announces appointment of Denelle J. Waynick as general counsel and corporate secretary
May 06, 2020: MyoKardia reports first quarter 2020 financial results
Feb 27, 2020: MyoKardia reports fourth quarter and full year 2019 financial results
Feb 20, 2020: MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

MyoKardia Inc, Key Facts
MyoKardia Inc, Key Employees
MyoKardia Inc, Key Employee Biographies
MyoKardia Inc, Major Products and Services
MyoKardia Inc, History
MyoKardia Inc, Subsidiaries
MyoKardia Inc, Key Competitors
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MyoKardia Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021